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Sodium-myoinositol 
cotransporter-1, SMIT1, mediates 
the production of reactive oxygen 
species induced by hyperglycemia 
in the heart
Anne Van Steenbergen1, Magali Balteau1, Audrey Ginion1, Laura Ferté1,  
Sylvain Battault1, Christophe de Meester de Ravenstein1, Jean-Luc Balligand2,3,  
Evangelos-Panagiotis Daskalopoulos1, Patrick Gilon4, Florin Despa5, Sanda Despa5,  
Jean-Louis Vanoverschelde1,6, Sandrine Horman1, Hermann Koepsell7, Gerard Berry8, 
Louis Hue1,9, Luc Bertrand1 & Christophe Beauloye1,6
Hyperglycemia (HG) stimulates the production of reactive oxygen species in the heart through 
activation of NADPH oxidase 2 (NOX2). This production is independent of glucose metabolism 
but requires sodium/glucose cotransporters (SGLT). Seven SGLT isoforms (SGLT1 to 6 and sodium-
myoinositol cotransporter-1, SMIT1) are known, although their expression and function in the heart 
remain elusive. We investigated these 7 isoforms and found that only SGLT1 and SMIT1 were expressed 
in mouse, rat and human hearts. In cardiomyocytes, galactose (transported through SGLT1) did not 
activate NOX2. Accordingly, SGLT1 deficiency did not prevent HG-induced NOX2 activation, ruling it 
out in the cellular response to HG. In contrast, myo-inositol (transported through SMIT1) reproduced 
the toxic effects of HG. SMIT1 overexpression exacerbated glucotoxicity and sensitized cardiomyocytes 
to HG, whereas its deletion prevented HG-induced NOX2 activation. In conclusion, our results show 
that heart SMIT1 senses HG and triggers NOX2 activation. This could participate in the redox signaling 
in hyperglycemic heart and contribute to the pathophysiology of diabetic cardiomyopathy.
Diabetes and hyperglycemia (HG) are major risk factors for cardiovascular diseases1,2. HG is also associated 
with adverse outcomes and increased mortality in patients with acute myocardial infarction, even in the absence 
of diabetes3–5. Prolonged exposure of cardiomyocytes to HG indeed has deleterious effects, such as alterations 
of myofibrillar structure and intercellular connections6, possibly resulting in cell death7–9. Several hypotheses 
have been proposed to explain the mechanism of such glucotoxicity. A major one is the exacerbated produc-
tion of reactive oxygen species (ROS) triggered by HG10. We have demonstrated previously that HG induces 
NADPH oxidase 2 (NOX2) activation (the major isoform of NOX in the heart), leading to ROS production 
independently of glucose metabolism11. Actually, HG-induced ROS production depends on sodium/glucose 
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co-transporters (SGLT), which typically use the downhill sodium gradient to drive sugar uptake, but not on clas-
sical facilitated-diffusion glucose transporters11,12. Indeed, phlorizin, a SGLT family-specific inhibitor, prevents 
HG-induced ROS production. Furthermore, α -methyl-D-glucopyranoside (α MG), a non-metabolizable glucose 
analogue, which is transported through SGLT, but not GLUT, mimics HG-induced ROS production in adult rat 
cardiomyocytes. On the other hand, 2-deoxyglucose (2DG), a glucose analogue with low affinity for SGLT but 
high affinity for GLUT, is unable to reproduce HG-induced ROS production11.
Seven SGLT isoforms have been described so far13:
•	 SGLT1 (encoded by SLC5a1) is mainly expressed in the brush border membranes of enterocytes and in prox-
imal tubules of the kidneys. It is responsible for active glucose absorption in both tissues14.
•	 SGLT2 (SLC5a2) is mainly expressed in the kidneys, playing a major role in glucose reabsorption in 
tubules15,16.
•	 SGLT3 (SLC5a4) has been regarded as a glucose “sensor” rather than a co-transporter17. Compared to SGLT1 
and SGLT2, its affinity for glucose is rather low (Km around = 20 mM), and the binding of sugar to human 
SGLT3 triggers membrane depolarization without any sugar transport. 2 genes are known in rodents (mice 
and rats): SLC5a4a coding for SGLT3a, and SLC5a4b coding for SGLT3b18. Sugar-induced current mediated 
by SGLT3a occurs only at acidic pH19. In contrast to human SGLT3, rodent SGLT3b transports sugar20.
•	 Little is known about SGLT4 (SLC5a8), except that it is a widely-expressed mannose transporter21.
•	 SGLT5 (SLC5a9) is exclusively expressed in the kidneys where it reabsorbs glucose and galactose22.
•	 SMIT1 and SGLT6 (also called SMIT2) are encoded by SLC5a3 and SLC5a11, respectively. They are expressed 
in the brain and kidneys where they co-transport myo-inositol with sodium23,24. Interestingly, their affinity 
for glucose is rather low15,25.
The tissue expression of SGLT1 and SGLT2 has been studied extensively, including in the heart. SGLT1 is 
known to be highly expressed in the heart26,27, even if its function in this organ remains poorly understood. 
There are conflicting reports about SGLT2 expression in cardiac tissues16,21,26,28,29, and little is known about the 
expression of other SGLT isoforms in the heart. To investigate the SGLT isoform involved in HG-induced ROS 
production, we studied the expression profile of the 7 SGLT isoforms in murine, rat and human hearts. We found 
that 2 SGLT isoforms, SGLT1 and SMIT1, are expressed in the heart and cardiomyocytes. We demonstrated, for 
the first time, that SMIT1 confers to cardiomyocytes the ability to detect HG and evokes NOX2 activation as well 
as ROS production.
Results
SGLT1 and SMIT1 are SGLT isoforms mainly expressed in the heart and cardiomyocytes. We 
firstly investigated the expression of all SGLT isoforms (SGLT1 to 6 and SMIT1) in the heart and purified cardi-
omyocytes of rats (Fig. 1) and mice (Fig. 2) and in human hearts (Fig. 3). Because of the poor specificity of com-
mercially-available antibodies for detecting the different isoforms26,30, we resorted to polymerase chain reaction 
(PCR) to specifically detect all the known isoforms. As expected, SGLT1 was expressed in the heart and cardi-
omyocytes of adult rats and mice as well as in the human heart. SGLT2, SGLT5 and SGLT6 were undetectable 
in all species (Fig. 1A, 2A and 3A). SGLT3 and SGLT4 were marginally expressed and became detectable in rats 
only through nested PCR, as proposed by O’Malley et al.31. SGLT3(b) was barely present in mice and humans, 
and SGLT4 was not apparent. In contrast, SMIT1 - like SGLT1 - was readily detectable in all species. SGLT1 and 
SMIT1 were then quantified and compared to their expression in positive control tissue (intestine for SGLT1 and 
brain for SMIT1) by quantitative-PCR (qRT-PCR). Compared to the intestine, SGLT1 mRNA was less expressed 
in the hearts of rats (Fig. 1B) and mice (Fig. 2B), but equally expressed in human hearts (Fig. 3B), in agreement 
with earlier findings26. SMIT1 mRNA expression was about 10-fold lower in the heart than in the brain of all 
species (Fig. 1C, 2C and 3C). Even if they were less expressed than in their respective bona-fide tissues, SMIT1 
and SGLT1 mRNA levels were comparable in the heart as well as in cardiomyocytes from rats (Fig. 1D) and mice 
(Fig. 2D). Human hearts exhibited higher SGLT1 compared to SMIT1 mRNA levels (Fig. 3D). Even if antibody 
specificity could be questioned, SMIT1 protein seemed to be detected by immunoblotting in rat (Fig. 1E) and 
mouse hearts (Fig. 2E). We confirmed that SMIT1 protein is also present in isolated cardiomyocytes in culture 
(Fig. 1E). In summary, SGLT1 and SMIT1 are SGLT isoforms significantly expressed in the heart.
Myo-inositol, transported through SMIT1, mimics HG-induced NOX2 activation and ROS 
production. Electrophysiological studies demonstrated high affinity of SGLT1 for galactose32, SGLT3(b) 
for 1-deoxy-glucose (1DG)20, SGLT4 for mannose21 and SMIT1 for myo-inositol33. We took advantage of this 
substrate specificity to ascertain which SGLT isoform could be involved in the HG response. Adult rat cardi-
omyocytes were exposed to these glucose analogues to test their capacity to activate NOX2 and to stimulate 
ROS production. NOX2 activation was evaluated by measuring the translocation of p47phox (a NOX2-activating 
subunit) close to caveolin-3 (cav3) and ROS production. α MG (transported through all SGLTs) induced NOX2 
activation, as already described34, but 2DG (transported through GLUT), 1DG (SGLT3) and mannose (SGLT4) 
did not. Interestingly, myo-inositiol triggered translocation of p47phox close to cav3 (Fig. 4A,B) and increased 
ROS production (Fig. 4C), thereby mimicking the toxicity induced by HG. Furthermore, Gp91dstat, a specific 
NOX2 inhibitor, prevented myo-inositol-induced ROS production (Fig. 4C). Finally, exposure of cardiomyocytes 
to galactose did not mimic the effect of HG or MI, indicating that SGLT1 does not mediate HG-induced ROS 
production. Taken together, our data suggest that SMIT1 is the SGLT isoform mainly responsible for the detection 
of increased glucose concentration, leading to ROS production.
www.nature.com/scientificreports/
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SGLT1 does not mediate HG-induced NOX2 activation. Next, we tested a SGLT1 knockout (KO) 
mouse model to evaluate SGLT1 involvement in HG-induced NOX2 activation. We first verified that SGLT1 KO 
mice exhibited a normal cardiac phenotype with normal left ventricular end-diastolic volume (LVEDV) (Fig. 5A), 
ejection fraction (EF) (Fig. 5B) and mass (Fig. 5C), under basal conditions. A glucose-galactose free diet, needed 
for SGLT1 KO mice survival, did not impact LV function (Fig. 5A–C). We also verified that SGLT1 deletion was 
not compensated by the expression of other SGLT isoforms in the heart (Fig. 5D) and did not affect NOX2 pro-
tein (gp91phox and p47phox) expression (Supplementary Fig. 1). Cardiomyocytes of SGLT1 KO and wild-type (WT) 
mice were then isolated, cultured and exposed to HG. SGLT1 deletion did not prevent p47phox translocation to cav3 
(Fig. 5E) or ROS production (Fig. 5F) in response to HG, confirming the lack of implication of SGLT1 in cardiac 
NOX2 activation by HG. It should be noted that glucose/galactose free diet type did not affect HG-induced ROS 
production although it induced a slight, but not significant, reduction in p47phox translocation after HG (Fig. 5E,F).
Figure 1. Detection of SGLT isoforms in rat heart and cardiomyocytes. (A) SGLT1, SGLT2, SGLT3b, 
SGLT4, SGLT5, SGLT6 and SMIT1 detection by RT-PCR and ethidium bromide-stained agarose gels on mRNA 
extracted from hearts (n = 4) and isolated cardiomyocytes (cardio. n = 4) of rats. Positive controls were intestine 
for SGLT1, kidney for SGLT2, SGLT3, SGLT4 and SGLT5 and brain for SGLT6 and SMIT1. mRNA copy 
number per μ g of RNA of SGLT1 (B) and SMIT1 (C) were measured in rat hearts (n = 4) and cardiomyocytes 
(n = 4) and compared to a positive control (n = 3). Data are means ± SEM. Statistical analysis was by one-way 
ANOVA. *Indicates values statistically different from corresponding control tissue, p ≤ 0.05. (D) Comparison 
of SGLT1 and SMIT1 mRNA copy numbers/μ g of RNA between hearts (n = 4) and cardiomyocytes (n = 4). 
Data were normalized to hypoxanthine guanine phosphoribosyl transferase (HPRT1) and expressed as Log10 
copy numbers/μ g RNA. (E) SMIT1 protein expression in rat heart compared to rat brain and in isolated rat 
cardiomyocytes in culture compared to total heart extract. eEF-2 detection is used as loading control. Full-
length blots are presented in Supplementary Figure 4.
www.nature.com/scientificreports/
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SMIT1 mediates HG-induced NOX2 activation and ROS production. We resorted to genetic manip-
ulation to evaluate the involvement of SMIT1 in HG-induced activation of NOX2 and ROS production. First, 
SMIT1 was overexpressed in adult rat cardiomyocytes with adenoviruses. Adenoviral infection induced a 3-fold 
increase of SMIT1 expression (Fig. 6A). Heightened SMIT1 protein expression was detected in plasma membrane 
fractions (Fig. 6B) and resulted in a significant 3-fold increment of myo-[3H]-inositol uptake (Fig. 6C). Under 
basal conditions or after infection with control adenovirus (Ad-Ctl), NOX2 activation (p47phox translocation and 
ROS production) mediated by increased glucose concentration in culture medium, was dose-dependent, being 
maximal at 21 mM glucose (Fig. 6D,E). However, after SMIT1 overexpression, maximally-augmented p47phox 
translocation to cav3 (Fig. 6D) and ROS production (Fig. 6E) were already observed with only 10 mM glucose, 
indicating that cardiomyocytes overexpressing SMIT1 were sensitized to glucose. In agreement, NOX2 inhibition, 
using 2.5 μ M Gp91dstat, blunted SMIT1 overexpression-induced ROS production at 10 mM glucose (Fig. 6F).
SMIT1 KO mice were used to provide a definitive proof of our new paradigm. As with SGLT1, the absence 
of SMIT1 affected neither the cardiac phenotype (Fig. 7A–C), the expression profile of other SGLT isoforms 
Figure 2. Detection of SGLT isoforms in mouse heart and cardiomyocytes. (A) SGLT1, SGLT2, SGLT3b, 
SGLT4, SGLT5, SGLT6 and SMIT1 detection by RT-PCR and ethidium bromide-stained agarose gels on 
mRNA extracted from hearts (n = 4) and isolated cardiomyocytes (cardio. n = 4) of mice. Positive controls 
were intestine for SGLT1, kidney for SGLT2, SGLT3, SGLT4 and SGLT5 and brain for SGLT6 and SMIT1. 
mRNA copy number per μ g of RNA of SGLT1 (B) and SMIT1 (C) were measured in mice hearts (n = 4) 
and cardiomyocytes (n = 4) and compared to a positive control (n = 3). Data are means ± SEM. Statistical 
analysis was by one-way ANOVA. *Indicates values statistically different from corresponding control tissue, 
p ≤ 0.05. (D) Comparison of SGLT1 and SMIT1 mRNA copy numbers/μ g of RNA between hearts (n = 4) and 
cardiomyocytes (n = 4). Data were normalized to ribosomal protein L32 (RPL32) and expressed as Log10 copy 
numbers/μ g RNA. (E) SMIT1 protein expression in murine heart compared to murine brain. eEF-2 detection is 
used as loading control. Full-length blots are presented in Supplementary Figure 5.
www.nature.com/scientificreports/
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(Fig. 7D), nor NOX2 protein (gp91phox and p47phox) expression (Supplementary Fig. 2). However, it drastically 
protected cardiomyocytes against hyperglycemic stress. Indeed, p47phox was not translocated close to cav3 
(Fig. 7E) and we did not observe an increase in ROS production (Fig. 7F) in SMIT1 KO cardiomyocytes in 
response to HG, in contrast to WT. The latter results definitively highlighted the role of SMIT1 in detecting 
high-glucose concentrations and in mediating ROS production in the heart.
As stated in the introduction section, we do argue that HG-induced NOX2 activation is not related to 
enhanced glycolysis and/or glucose metabolism. However, we had to verify that SMIT1 deletion did not 
Figure 3. Detection of SGLT isoforms in human hearts. (A) SGLT1, SGLT2, SGLT3, SGLT4, SGLT5, SGLT6 
and SMIT1 detection by RT-PCR and ethidium bromide-stained agarose gels on mRNA extracted from non-
failing human hearts (n = 4). Positive controls were intestine for SGLT1, kidney for SGLT2, SGLT3, SGLT4 
and SGLT5, and brain for SGLT6 and SMIT1. mRNA copy numbers/μ g of SGLT1 (B) and SMIT1 (C) RNA 
were measured in non-failing human hearts (n = 7) and compared to a positive control (n = 3). The clinical 
characteristics of patients are presented in Supplementary Table 1. (D) Comparison of SGLT1 and SMIT1 
mRNA copy numbers/μ g of RNA in human hearts (n = 7). Data were normalized to RPL32 and expressed as 
Log10 copy numbers/μ g RNA. Data are means ± SEM. Statistical analysis was by Student’s t-test. *Indicates 
values statistically different from (C) corresponding control tissue (D) hSGLT1 mRNA expression, p ≤ 0.05.
www.nature.com/scientificreports/
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interfere with cardiac glucose metabolism and more particularly that the inhibition of HG-induced ROS pro-
duction in KO cells could not be attributed to a drastic reduction in glucose entry under HG. The rate of [2-3H] 
glucose uptake, a usual way to evaluate global glucose uptake, was measured in SMIT1 KO mice in comparison 
to WT at 5 (LG) and 21 mM glucose (HG) and in response to 3*10−9M of insulin. The absence of SMIT1 did not 
reduce glucose uptake under LG, HG or insulin stimulation (Fig. 7G). In contrast, a slight but non-significant 
increase in insulin response was observed. Similar data were obtained for 2[3H]-Deoxy-D-glucose uptake, 
another experimental procedure to evaluate glucose entry via GLUT transporters. Once again, these observa-
tions reinforce our hypothesis and data, disclosing that HG-induced ROS production is not related to changes 
in glucose metabolism.
Figure 4. Effect of glucose analogues on NOX2 activation and ROS production. (A) Effect of 5 mM (LG) or 
16 mM of glucose (HG), α -Methyl-D-glucose (α MG), 2-deoxy-glucose (2DG), galactose (Gal), 1-deoxy-glucose 
(1DG), mannose (Man) or myo-inositol (MI) (under 5 mM glucose background) on HG-induced p47phox 
co-localization close to cav3. The close proximity between p47phox and cav3, as detected by PLA, was assessed 
90 min after exposure to glucose analogues. Typical pictures of the effect of glucose analogues are shown in (B). 
White lines correspond to 20 μ m. (C) ROS production measured 2 h after LG, HG, α MG, 2DG, Gal, 1DG, Man 
and MI. 2.5 μ M of Gp91dstat or scrambled peptide were added 15 min before glucose analogues. The data are 
means ± SEM, (n = 4). Statistical analysis was by (A) one-way ANOVA and (C) two-way ANOVA. $Indicates 
values statistically different from LG, p ≤ 0.05. *Indicates values statistically different from the corresponding 
HG sample without treatment, p ≤ 0.05.
www.nature.com/scientificreports/
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Figure 5. Impact of SGLT1 deletion on HG-induced NOX2 activation and ROS production. (A) LVEDV, 
(B) EF and (C) LV mass were measured by echocardiography of SGLT1 WT under usual diet (n = 10), of SGLT1 
WT submitted to glucose and galactose free diet (glu/gal free diet, n = 10) and of SGLT1 KO (n = 10) mice. 
Echocardiographic data in M-mode and 2D parasternal long axis are presented in Supplementary Table 4. 
(D) Detection of SGLT1, SGLT2, SGLT3b, SGLT4, SGLT5, SGLT6 and SMIT1 by RT-PCR and ethidium 
bromide-stained agarose gels on mRNA extracted from the hearts of SGLT1 KO mice (n = 3) compared to WT 
mice (n = 3). Positive controls were intestine for SGLT1, kidneys for SGLT2, SGLT3, SGLT4 and SGLT5, brain 
for SGLT6 and SMIT1. (E) Quantification of HG-induced p47phox translocation close to cav3 in SGLT1 WT 
mice (with and without glu/gal free diet) compared to SGLT1 KO mice. Adult mouse cardiomyocytes were 
isolated from SGLT1 WT (n = 7), SGLT1 WT submitted to glu/gal free diet (n = 7) and SGLT1 KO (n = 7) 
hearts. PLA was performed 90 min after stimulation with HG and compared to LG. White lines correspond to 
20 μ m. (F) ROS production induced by 3 h of incubation with HG in cardiomyocytes isolated from SGLT1 WT 
(n = 6), SGLT1 WT submitted to glu/gal free diet (n = 6) and SGLT1 KO (n = 6) mice. Data are means ± SEM. 
Statistical analysis was by two-way ANOVA. $Indicates values statistically different from LG, p ≤ 0.05.
www.nature.com/scientificreports/
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Discussion
The major findings of this study are that (i) SMIT1 is expressed as much as SGLT1 in the heart and (ii) detects 
elevated glucose concentration, leading to NOX2 activation and ROS production. It could therefore participate in 
redox signalling in normal and diabetic hearts. To the best of our knowledge, this is the first evidence of SMIT1’s 
role in cardiac tissue.
Figure 6. Impact of SMIT1 overexpression on NOX2 activation and ROS production. Adult rat 
cardiomyocytes were infected with adenoviruses (24 h, 200 MOI) expressing SMIT1 (Ad-SMIT1) or  
β -galactosidase (Ad-Ctl). (A) SMIT1 mRNA level measured by qRT-PCR (n = 3). Data were normalized to 
HPRT1 and expressed as relative expression vs Ad-Ctl. (B) SMIT1 protein expression in plasma membrane 
fractions obtained after cellular fractionation. Full-length blots are presented in Supplementary Figure 6. 
(C) Quantification of picomoles myo-[3 H]inositol uptake per min and mg of proteins (n = 4). (D) p47phox 
translocation close to cav3 (n = 6) and (E) ROS production (n = 7) in response to increased glucose 
concentration (5–10 and 21 mM of glucose). (F) Gp91dstat and scrambled peptide were added 15 min prior to 
glucose (5 or 10 mM glucose). ROS production was quantified 2 h after change in glucose concentration (n = 3). 
Data are means ± SEM. Statistical analysis was by (A–C) Student’s t-test or (D,E,F) two-way ANOVA. $Indicates 
values statistically different from LG, p ≤ 0.05. *Indicates values statistically different from (A–E) Ad-Ctl, and 
(F) scr, p ≤ 0.05.
www.nature.com/scientificreports/
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The SGLT2 isoform in the SGLT family has been widely explored in the literature because of its growing 
interest as a new therapeutic target in the treatment of type 2 diabetes (T2D). Indeed, SGLT2 inhibitors (SGLT2i) 
reduce plasma glucose levels by inhibiting glucose reabsorption, without targeting the major pathophysiological 
defects in T2D (insulin resistance and impaired insulin secretion). Interestingly, the EMPA-REG OUTCOME 
Trial recently showed that treatment of T2D patients at high risk for cardiovascular events with empagliflozin 
Figure 7. Impact of SMIT1 deletion on HG-induced NOX2 activation and ROS production. (A) LVEDV, 
(B) EF and (C) LV mass were measured by echocardiography of SMIT1 WT (n = 10) and KO (n = 10) mice. 
Echocardiographic data in M-mode and 2D parasternal long axis are presented in Supplementary Table 5.  
(D) Detection of SGLT1, SGLT2, SGLT3b, SGLT4, SGLT5 and SGLT6 by RT-PCR and ethidium bromide-stained 
agarose gels on mRNA extracted from the hearts of SMIT1 KO mice (n = 3) compared to WT mice (n = 3). 
Positive controls were intestine for SGLT1, kidneys for SGLT2, SGLT3, SGLT4 and SGLT5, brain for SGLT6 and 
SMIT1. (E) Quantification of HG-induced p47phox translocation close to cav3 in SMIT1 WT mice compared to 
SMIT1 KO mice. Adult mouse cardiomyocytes were isolated from SMIT1 WT (n = 4) or SMIT1 KO (n = 4) hearts. 
PLA was performed 90 min after stimulation with HG and compared to 5 mM of glucose. White lines correspond 
to 20 μ m. (F) ROS production induced by 3 h of incubation with HG in cardiomyocytes isolated from SMIT1 WT 
(n = 6) or SMIT1 KO (n = 6) mice. (G) Cardiac glucose uptake in SMIT1 WT (n = 6) vs KO (n = 6) mice was 
measured under LG, HG and after insulin (3.10−9 M insulin 30 min). Data are means ± SEM. Statistical analysis 
was by two-way ANOVA (E–F). $Indicates values statistically different from LG, p ≤ 0.05.
www.nature.com/scientificreports/
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(the most selective SGLT2i) reduced major cardiovascular events, including death from cardiovascular causes, 
compared to placebo35. However, conflicting results still persist regarding its expression in the heart16,26,29. In the 
present study, we confirmed that SGLT2 is expressed neither in the cardiac tissue, nor in isolated cardiomyocytes, 
excluding a direct action of SGLT2i on heart. The cardiovascular protection conferred by empagliflozin could be 
due to increased salt excretion and decreased blood pressure. Identifying the role of SGLT2 in the vasculature 
requires further investigation.
In contrast to SGLT2, we confirmed that SGLT1 is highly expressed in the heart in agreement with earlier 
studies26,27. Our initial hypothesis was that SGLT1 sensed increased glucose concentrations, leading to ROS pro-
duction, independently of glucose metabolism11. However, the high affinity of SGLT1 for glucose (Km = 0.5 mM) 
makes this paradigm unlikely. Theoretically, glucose transport through SGLT1 should be maximal under normo-
glycemia, protecting the cells against HG, unless there is a change in its expression or translocation. Our results 
definitely ruled out a role of SGLT1 in NOX2-dependent ROS production in the heart. On the one hand, galac-
tose, a SGLT1 substrate, did not reproduce HG-induced NOX2 activation. Slightly increased ROS production due 
to galactose has been observed, although the latter was not sensitive to the NOX2 inhibitor. On the other hand, 
SGLT1 deficiency did not prevent cardiomyocytes from producing ROS in response to HG. Moreover, we showed 
that SGLT1 deletion did not impact LV function under basal conditions. Recent findings showed that SGLT1 
protein is actually rather localized in the heart capillaries than in myocytes sarcolemma36. Taken all together, one 
may speculate that dual SGLT2/SGLT1 inhibitor should have limited cardiac side effects although they would be 
more effective in reducing glycemia37.
SMIT1, the third member of the Na+/glucose cotransporter family (SLC5a3), has been mainly studied in the 
brain where its function is to transport myo-inositol, an important precursor of inositol phosphates and phos-
pholipids that are central in membrane and cell signalling33. We demonstrated, for the first time, that SMIT1 is 
expressed in mouse and rat hearts and cardiomyocytes, as well as in human hearts. SMIT1 expression data in 
human hearts come from patients with significant mitral disease without evidence of severe LV dilatation or dys-
function, referred for surgery (mitral valve plasty or replacement). We also verified that SMIT1 expression was 
similar in patients without any cardiovascular disease (heart rejected from transplant) (Supplementary Fig. 3). 
Compelling evidence favoured SMIT1 as HG sensor in the heart. Myo-inositol completely reproduced the toxic 
effects of HG, leading to NOX2 activation and ROS production. Furthermore, SMIT1 overexpression sensitized 
cardiomyocytes to glucose. Indeed, SMIT1 overexpression induced NOX2 activation and ROS production at only 
10 mM of glucose, being nearly maximal. Finally, SMIT1 deletion prevented HG-induced NOX2 activation and 
ROS production.
Since SMIT1 deletion has no impact on cardiac phenotype, its physiological role in the heart remains to be 
elucidated. As in the brain, it could be involved in several transduction signals that have still to be determined. 
Interestingly, SMIT1 barely influenced glucose uptake in the heart in normoglycemia as well as in hyperglycemic 
conditions. Therefore, NOX2 activation could not be related to enhanced glucose uptake in HG but probably 
depends on a signalling cascade activated downstream of SMIT1. In line with this hypothesis, growing evidence 
favours SGLT transporters as glucose sensors beyond their role as active glucose transporters, triggering ionic 
signalling (Na+ and Ca2+ 14,31,38, via the sodium-calcium exchanger (NCX)39,40) into the cells owing to changes in 
extracellular glucose concentration28,30,39,41,42. Protein kinase C (PKC)-β , a calcium-dependent serine/threonine 
kinase, could be the link between ionic changes downstream of SMIT1 and NOX2 activation, as its inhibition 
prevented HG-induced ROS production34.
NOX2 seems to be the main source of ROS in our experimental model as the NOX2 inhibitor, gp91dstat, 
inhibited almost completely the HG-induced ROS production (Fig. 4C and ref. 11). However, one may not 
exclude that in the long term mitochondria also contribute to ROS production under hyperglycemic conditions. 
Indeed, NOX2 activation could trigger or enhance a subsequent mitochondrial ROS production43.
The pathophysiological role of acute HG-induced ROS production in the heart remains to be ascertained. 
Increased ROS production induces cell death in isolated cardiomyocytes in culture11 and is usually considered to 
be a key element contributing to the onset of diabetic cardiomyopathy and favouring heart failure. HG-induced 
ROS also triggers insulin resistance in cardiomyocytes. Indeed, incubation of cardiomyocytes with HG resulted 
in insulin resistance within 24 h, whereas NOX2 inhibition restored insulin signalling11. However, as previously 
advocated, cardiac insulin resistance state protects the heart from fuel overload in dysregulated metabolic states44. 
Therefore, NOX2-dependent ROS production, downstream of SMIT1, could be an “acute” intermediate signal, 
favouring anti-oxidant responses, inducing metabolic preconditioning and protecting cells against further fuel 
overload, including HG.
Conclusion
In the present study, we highlighted that, besides SGLT1, SMIT1 is expressed in the heart. SMIT1 is able to detect 
increased extracellular glucose levels and triggers signalling leading to NOX2 activation and ROS production. To 
the best of our knowledge, ours is the first study which examines SMIT1 in the heart and proposes that it acts as a 
glucose sensor. Further investigation is required to ascertain its physiological and pathological functions.
Methods
Animals. Animal handling was approved by the Animal Research Committee of the Université catholique de 
Louvain (2012/UCL/MD/003) and conformed to the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996). SGLT1 KO mice and SMIT1 
KO mice were generated as described elsewhere14,45.
Materials. D-(+ )-glucose (G8272), methyl-α -D-glucopyranoside (M9376), D-(+ )-mannose (M6020), 
myo-inositol (I5125), D-(+ )-galactose (G0750), 2-deoxy-D-glucose (D3179) and 1-deoxy-D-glucose (S404497) 
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were purchased from Sigma. The antibodies used were: SMIT1 (C18843) from Assay BioTech and (Ab113245) 
from Abcam, Caveolin-3 (sc-7665) from Santa Cruz Biotechnology, p47phox (07–497) from Millipore, and gp91phox 
(Sc-5827) from Santa Cruz. Gp91dstat peptide and corresponding scrambled peptide were kindly provided by 
V. Stroobant (Ludwig Institute, Brussels, Belgium).
Isolation and culture of adult rat and mice cardiomyocytes. Adult rat cardiomyocytes were isolated 
after heart perfusion with collagenase type II (1 mg/ml, Worthington), then purified and cultured, as described 
previously46. Primary cultures of cardiomyocytes were incubated with different sugar concentrations for the indi-
cated periods of time, as detailed in the figure legends.
Adult mice were anesthetized with a mixture of ketamine (80 mg/kg) and xylazine (10 mg/kg). Cardiomyocytes 
were isolated, as described34, with the following modifications: hearts were perfused with Liberase DH enzyme 
(0.625 mg/heart, Roche) and trypsin (2.1 mg/heart, Life Technologies 15090–046). The cells were then purified, 
cultured and plated on laminin-coated dishes, and incubated for 1 h in fresh minimum essential medium (MEM) 
with Hank’s salts (Life Technologies 11575–032) supplemented with L-glutamine (2 mM), bovine serum albumin 
(BSA) 100 μ g/ml, penicillin (100 U/ml) and streptomycin (100 μ g/ml). Primary cultures of mice cardiomyocytes 
were treated as adult rat cardiomyocytes.
Human biopsies. Human LV biopsies were obtained during surgery from patients operated because of 
severe mitral disease but without any evidence of LV dilatation or dysfunction (baseline clinical characteristics 
of patients are presented in Supplementary Tables). This protocol was approved by the local ethics committee 
(Comité éthique hospitalo-facultaire des Cliniques Universitaires St. Luc, Brussels, Belgium) and signed informed 
consent was obtained before surgery. All experimental procedures were performed in accordance with relevant 
guidelines and regulations. All cardiac tissues were immediately frozen in liquid nitrogen and stored at − 80 °C. 
Brain, intestine and kidney samples, as positive controls, were residual material from surgery.
RNA extraction and RT-PCR. Total mRNA was extracted from organs with an RNA extraction kit (RNeasy 
mini-kit Qiagen 74106) and from cardiomyocytes according to a chloroform/isopropanol procedure (Tripure 
Isolation reagent, Roche 11667165001). All RNA preparations were subjected to on-column treatment with 
RNAse-free DNAse set (Qiagen 79254). mRNAs were quantified with nanodrop (Thermo Scientific). Reverse 
transcription was performed for 1 h at 37 °C with 0.4 to 1 μ g RNA and iScriptTM cDNA synthesis kit (Bio-Rad 
laboratories 1708891). All PCRs contained 5 μ l of RT reaction and 0.05 μ M of forward and reverse primers in 50 μ l 
volume. PCR was performed with GoTaq G2 DNA polymerase (Promega M7845), and reactions were heated to 
95 °C for 2 min, followed by up to 45 cycles of 95 °C for 30 s, 60–65 °C for 30 s, 72 °C for 40 s and then heated at 
72 °C for additional 5 min in a MJ MiniTM Gradient Thermal Cycler (Biorad PTC-1148). The PCR products were 
separated by agarose gel electrophoresis (0.8 to 2% wt/v) and stained with ethidium bromide. All PCR products 
were verified by sequencing (Beckman Coulter Genomics). Nucleotide sequences of the primers used are summa-
rized in Supplementary Tables. qRT-PCR was performed on IQ5 (Bio-Rad) with qPCR Core kit from Sybergreen 
(Eurogentec RT-SN-10–05-NR). The mRNA level for each gene in each sample was normalized to a housekeeping 
gene. Standards consisted of 10-fold dilutions of plasmids carrying the PCR fragment of interest (pcDNA3-Topo, 
Invitrogen). The nucleotide sequences of primers used are summarized in Supplementary Tables.
ROS measurement. Intracellular ROS production was measured, as described11 previously, by evaluating 
oxidation of the cell permeable fluorescent probe 2′ ,7′ -dihydrodichlorofluorescein diacetate (Invitrogen), which 
becomes fluorescent when oxidized by ROS.
Preparation of cytosol and membrane fractions. Cytosol and membrane fractions were obtained, 
as described previously47. After appropriate stimulation, cardiomyocytes were washed 3 times in ice-cold 
Dubbelcco’s phosphate-buffered saline (PBS) and scraped in buffer A containing 20 mM Tris pH 7.5, 2.5 mM 
EGTA, 0.1 mM EDTA, 0.1 M NaF, 2 mM dithiothreitol and protease inhibitor cocktail (cOmplete Mini from 
Roche). Cells were disrupted by sonication on ice (five 4-s bursts) and then centrifuged at 1,500 g for 10 min at 
4 °C. Supernatants were collected (cytosolic fraction) and centrifuged at 100 000 g for 45 min at 4 °C. The pellets 
were solubilized in buffer A containing 1% triton X-100, sonicated and centrifuged at 15 000 g for 15 min at 4 °C. 
The resulting supernatants were membrane fractions.
Immunoblotting analysis. Protein content was measured by the Bradford method with BSA as stand-
ard. Immunoblotting was performed with extracts separated on 8% (SMIT1, p47phox, gp91phox) or 12% (Cav3) 
SDS-PAGE and transferred to polyvinylidene difluoride membranes which were blocked with BSA (5% wt/v) 
and then with corresponding antibodies. After incubation with appropriate secondary antibody (anti-rabbit and 
anti-goat), proteins were visualized by electrochemical luminescence (Pierce).
Protein co-localization by in situ proximity ligation assay (PLA). p47phox co-localization with cav3 
was measured, as described34 previously and visualized as red fluorescent dots appearing where both proteins 
co-localize. Nuclei were stained with DAPI. Protein staining was visualized with a Zeiss.Imager.Z1 microscope 
equipped with an ApoTome device. Red fluorescent dots were quantified by AxioVision Rel 4.8 software.
SMIT1 adenovirus generation and cardiomyocytes infection. SMIT1 adenoviruses were 
generated with the Adeasy system (Agilent Technologies). Briefly, SMIT1 cDNA was amplified by PCR 
from rat brains with the following primers: sense 5′-ATGAGGGCTGTGCTGGAGAC-3 and antisense 
5′ -TCATAAGGAGAAATAAACAAACAT-3′ , and inserted into pShuttle-CMV vector. pShuttle-SMIT1 was 
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recombined in pAdEasy vector. Adenovirus production and amplification were realized as per the manufacturer’s 
instructions.
Adult rat cardiomyocytes were infected (200 multiplicity of infection) with adenoviral construction 
(Ad-SMIT1 and β -galactosidase adenoviruses served as control: (Ad-Ctl). SMIT1 expression was assessed by 
qRT-PCR, cell fractionation and myo-inositol uptake, 24 h after cardiomyocyte infection.
Myo-inositol uptake. 100,000 cells were infected (Ad-SMIT1 or Ad-Ctl) for 24 h, then rinsed with PBS 
and incubated for 15 min at 37 °C in medium containing 1.2 mM MgSO4, 1.2 mM KH2PO4, 4.7 mM KCl, 120 mM 
NaCl, 2.5 mM CaCl2 and 25 mM NaHCO3 in 5% CO2 at pH 7.4. This medium was replaced by the same solution 
containing 25 μ M MI (0.08 μ Ci/1μ mol) for 1 min at 37 °C. The cells were then rinsed twice with the same solution 
containing 3 mM phlorizin and scrapped in 100 mM NaOH. Myo-inositol uptake was linear from 30 s to 5 min.
Glucose uptake. Glucose uptake was measured as described previously46,48, by [2-3H]glucose detritiation 
rate which occurs after glucose phosphorylation during rapid isomerization of hexose-6-phosphate catalyzed by 
phosphoglucose isomerase. Tritium from C2 of glucose is released as tritiated water in supernatant, which can 
be separated from tritiated glucose by chromatography on anion exchange resin (borate form) and measured by 
scintillation counter.
Echocardiography. Two-dimensional echocardiography was performed on mice with a Vevo 2100 Imaging 
system (VisualSonics), as described previously49. Mice were anesthetized by isoflurane inhalation at concentra-
tions of 5% (induction) and 2,5% (maintenance) in 100% oxygen.
Statistical analysis. All values are expressed as means ± SEM. Samples are biological replicates. 
Comparisons were made by ANOVA, followed by Bonferroni post hoc testing (detailed in the figure legends). 
p < 0.05 values were considered to be statistically significant.
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